Chronic Kidney Disease

Among patients who suffer an in-hospital cardiac arrest, acute kidney injury (AKI) raised the risk of all-cause in-hospital mortality from about 30% to more than 60%.

A study suggests that for patients with chronic kidney disease (CKD), the more components of metabolic syndrome present, the higher that patient’s risk of adverse cardiovascular outcomes.

This new study from South Korea investigated if patients with cancer could be at potential greater risk of kidney failure and found connections with several cancer types.

Patients with nephrotic syndrome were far more likely than healthy controls to suffer end-stage kidney disease, particularly if they had focal segmental glomerulosclerosis or membranous nephropathy.

Major polypharmacy use was found to increase risk of mortality between 22% and 135% for American adults with chronic kidney disease (CKD) in this subanalysis of data from the REGARDS study.

This recent study compared orthostatic hypotension outcomes among 2 patient populations, both with chronic kidney disease (CKD), who were or were not living with diabetic nephropathy (DNP).

New research indicates an association between longer chronic kidney disease duration and taste dysfunction.

About 4 in 10 patients with chronic kidney disease will have “early rapid decline,” a trajectory more likely if the patient also has diabetes.

Inconsistent application and measure of the Kidney Disease Improving Global Outcomes definition of acute kidney injury (AKI) prompted this review, which used a measure of 75% agreement when defining consensus.

This new study from Japan investigated possible relationships between tubular injury, COVID-19 severity, and inflammatory markers with development of acute kidney injury.

The dialysis company faces a $100M fine for each of 2 antitrust counts.

Positive drug trial results suggest promising outcomes for adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

Exome sequencing of patients with kidney disease and their families identified 17 different monogenetic causes of kidney disease.

A new study says that treating iron deficiency therapy may improve outcomes in patients with chronic kidney disease, even if they don’t have anemia.

Considerable evidence shows sodium-glucose co-transporter-2 inhibitors have cardioprotective benefits, but new research elucidates the ways in which the drugs can also have positive renal impacts.

The proposed changes to the payment model for end stage renal disease (ESRD) would make it the first payment model under the CMS Innovation Center to directly address health equity by incentivizing increased rates of home dialysis and kidney transplants.

The math is straightforward: The best way for employers and insurers to avoid paying for dialysis is to invest in preventive care.

How therapeutic advances can address all 3 conditions was the topic of a symposium Friday during the 81st Scientific Sessions of the American Diabetes Association (ADA), “The Intersection of Diabetes, Heart Failure and Kidney Disease: Challenges and New Insights.”

Adults with normal kidney function who have comorbid depression are more likely to experience a decline in kidney function and have mental and physical impairments from that decline.

Eligible patients who are not waitlisted for kidney transplants lose profound opportunities and are subject to racial and socioeconomic disparities regarding waitlist placement, a study showed.

Dapagliflozin substantially slowed the progression of chronic kidney disease (CKD) in patients with immunoglobulin A nephropathy, according to a new study.

Older patients with chronic kidney disease face higher risks of intensive care unit admission and in-hospital mortality if they contract COVID-19, a new report shows.

The founder of the Renal Support Network discusses why patients with chronic kidney disease want Congress to change Medicare policy to allow payment for oral treatments for anemia caused by iron deficiency.

About 5.4% of patients with end-stage renal disease (ESRD) who begin renal replacement therapy as children go on to have vascular events, and 4.1% of those patients die as a result of vascular events, though the real incidence rates are likely higher, according to new research.

A new analysis reveals penalties levied under a CMS program to improve the quality of care at dialysis centers did not lead to significant change.